tirzepatide corona confers wide range of benefits in type 1 diabetes Tirzepatide - Ascend Vitality

All gastrointestinal disorder events were mild to moderate in severity

Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025

(PubMed) Kaur P, Rizk NM, Ibrahim S, et al

Healthcare providers emphasize the importance of monitoring thyroid hormone levels and blood glucose to avoid therapeutic duplication warnings and the risk of thyroid hormone imbalance

Any off-label use should be discussed with a clinician who will consider risks and monitor closely